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Abstract
Borrelia hermsii, a causative agent of relapsing fever of humans in western North America, is maintained in enzootic cycles
that include small mammals and the tick vector Ornithodoros hermsi. In mammals, the spirochetes repeatedly evade the
host’s acquired immune response by undergoing antigenic variation of the variable major proteins (Vmps) produced on
their outer surface. This mechanism prolongs spirochete circulation in blood, which increases the potential for acquisition
by fast-feeding ticks and therefore perpetuation of the spirochete in nature. Antigenic variation also underlies the relapsing
disease observed when humans are infected. However, most spirochetes switch off the bloodstream Vmp and produce a
different outer surface protein, the variable tick protein (Vtp), during persistent infection in the tick salivary glands. Thus the
production of Vmps in mammalian blood versus Vtp in ticks is a dominant feature of the spirochete’s alternating life cycle.
We constructed two mutants, one which was unable to produce a Vmp and the other was unable to produce Vtp. The
mutant lacking a Vmp constitutively produced Vtp, was attenuated in mice, produced lower cell densities in blood, and was
unable to relapse in animals after its initial spirochetemia. This mutant also colonized ticks and was infectious by tick-bite,
but remained attenuated compared to wild-type and reconstituted spirochetes. The mutant lacking Vtp also colonized ticks
but produced neither Vtp nor a Vmp in tick salivary glands, which rendered the spirochete noninfectious by tick bite. Thus
the ability of B. hermsii to produce Vmps prolonged its survival in blood, while the synthesis of Vtp was essential for
mammalian infection by the bite of its tick vector.
Citation: Raffel SJ, Battisti JM, Fischer RJ, Schwan TG (2014) Inactivation of Genes for Antigenic Variation in the Relapsing Fever Spirochete Borrelia hermsii
Reduces Infectivity in Mice and Transmission by Ticks. PLoS Pathog 10(4): e1004056. doi:10.1371/journal.ppat.1004056
Editor: Jenifer Coburn, Medical College of Wisconsin, United States of America
Received January 7, 2014; Accepted February 24, 2014; Published April 3, 2014
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, MD, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: tschwan@niaid.nih.gov
Introduction
Borrelia hermsii is one of many human pathogens that escapes the
host’s adaptive immune response by changing its outer surface
proteins through antigenic variation [1–3]. This mechanism of
immune evasion involves a large repertoire of genes that encode
dominant outer surface proteins, the variable major proteins
(Vmps), only one of which is produced by a single spirochete at
any one time [4]. Most B. hermsii cells in a bloodstream population
produce the same Vmp, which defines the serotype that is
antigenically distinct from other populations of cells that precede
and follow it during the course of infection. However, within the
population there are rare antigenic variants that arise spontane-
ously, which have different Vmps and can be the founders for the
next dominant serotype. This switch in the spirochete that results
in the production of a different Vmp occurs by gene conversion, a
nonreciprocal gene transfer of a silent promoter-less vmp gene
cassette, which is recombined into the single vmp expression site
near the telomere of the linear plasmid lp28-1 [1,5–7].
As the spirochetes achieve high cell densities in the blood, the
bacteria are cleared by the host’s immune response, dominated by
an IgM antibody response directed at the Vmp on the surface of
the spirochetes [8–12]. Spirochetes coated by a Vmp that is
antigenically distinct from the majority of the population avoid this
immune attack, replicate and produce a new population of
bacteria in the host (the relapse), which in turn is attacked by a
new IgM antibody response. This process of antigenic variation
can repeat for many cycles in the mammalian host [4,13,14].
When people are infected with this spirochete, the resulting illness
is characterized by repeated cycles of acute febrile episodes and
remission when the patient feels almost normal, hence the name
relapsing fever. In nature, this spirochete’s ability to produce
repeated bacteremias in the peripheral blood of small mammals
increases its potential to be acquired by its obligate, fast-feeding
tick vector Ornithodoros hermsi [15].
Each antigenically distinct B. hermsii Vmp is encoded by a
different vmp cassette. To date, 59 silent cassettes have been
identified [16] and the Vmps they encode segregate into two
families based on their molecular mass. The variable small
proteins (Vsps) are approximately 22 kDa, while the variable large
proteins (Vlps) are approximately 37 kDa [17,18]. The silent
cassettes are located on the lp28-1 vmp expression plasmid and
other linear plasmids of similar size [16].
The mechanism of antigenic variation in B. hermsii has been
studied extensively by examining the DNA sequences surrounding
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the vmp gene in the active expression site and comparing them to
the DNA surrounding the gene in its silent location for several
different serotypes [6,16,17,19–21]. Previously published sequenc-
es surrounding the expression locus and 12 kb of DNA immedi-
ately upstream on the lp28-1 plasmid [Genbank accession
numbers DQ218042 (B. hermsii HS1) and CP000273 (B. hermsii
DAH)] [16,19] indicated key genetic elements that are involved in
both the DNA recombination and expression of a vmp. A sigma-70
type promoter and a ribosome-binding site (Fig. 1) allow for
production of the Vmp. Directly upstream of the promoter is a
string of 13 T residues (16 T residues in the HS1 strain) [17,19,20]
that enhances transcription from the promoter [22]. Upstream of
this T-rich region are three sets of imperfect inverted repeats that
potentially form stem-loop structures. These inverted repeats are
unique to the expression plasmid lp28-1 and therefore may play a
role in expression or recombination of the vmp gene [19]. The
Upstream Homology Sequence (UHS) and the Downstream
Homology Sequence (DHS) flanking the vmp may be necessary
for the recombination of a new vmp gene into the expression site
[16,17]. The UHS contains approximately 60 nucleotides and
encompasses the transcriptional start site and part of the coding
sequence of the signal peptide of the vmp, and the DHS is a 214 bp
nucleotide sequence downstream of the coding sequence.
When O. hermsi ticks acquire the spirochetes from an infected
mammal, the bacteria switch from producing the bloodstream
Vmp to producing another major outer surface protein, the
variable tick protein (Vtp) [23,24]. The vtp gene is transcribed from
its own promoter, which is located on a larger linear plasmid that
varies in size from 35 to 53 kb among different B. hermsii isolates
[25–27]. In contrast to the repertoire of vmp cassettes, there is only
one copy of vtp in the spirochete’s genome [26]. When B. hermsii
expresses a vmp gene, the vtp expression is down-regulated [23,26].
However, when B. hermsii is acquired by ticks, this reciprocal
synthesis involving the two expression sites is reversed, with Vtp
replacing the bloodstream Vmp [26]. Thus two key components of
the B. hermsii life cycle include the ability to sequentially produce
antigenically distinct serotypes in the mammalian bloodstream,
and to replace the Vmps with a different major surface protein,
Vtp, when infecting ticks.
We report here the first genetic study of the roles of the Vmps
and Vtp in the infectivity and transmissibility of B. hermsii in mice
and ticks. We constructed a mutant (Vmp2) that was unable to
produce a Vmp or undergo antigenic variation. We then
reconstituted the mutation to wild-type (Vmp+R), and followed
the strains through the infectious cycle with ticks and mice. We
show that the Vmp2 mutant colonized ticks but caused a reduced
initial spirochetemia in immunocompetent mice and was unable to
relapse, compared to the wild-type and Vmp+R reconstituted
strains. We also show that the Vmp2 mutant maintained a
persistent infection in immunodeficient SCID mice, but again
produced lower cell densities compared to the wild-type and
Vmp+R strains. We also tested a mutant (Dvtp) unable to produce
Vtp and show that, while this mutant was also able to persistently
colonize ticks, the inability of B. hermsii to produce Vtp rendered
the spirochetes noninfectious by tick bite.
Results
Construction of a Vmp-minus mutant (Vmp2)
We constructed a Vmp-minus mutant (Vmp2) by replacing a
segment of DNA on plasmid lp28-1 involved in the expression and
recombination of a new vmp gene with a kanamycin-resistance
cassette (Fig. 1). The deleted region included the first 340 bp of the
1107 bp vlp7 gene in the expression site, the UHS, the promoter
and ribosome binding site, the T-rich region, and the proximal
inverted repeat (Fig. 1). PCR analysis of the mutant confirmed that
the kanamycin-resistance cassette was inserted into the lp28-1 in
place of the deleted region (data not shown). Sequencing of the
amplicons also confirmed the insertion.
Southern blot analysis of genomic DNA from the wild-type
spirochete and two Vmp2 clones digested with PsiI or MfeI (sites
indicated on Fig. 1) and probed with vlp7 or kan probes also
confirmed that the mutation occurred in the telomeric expression
site and not in the silent vlp7 cassette on another plasmid (Genbank
accession no. CP000274) [16]) or into a rare long expression
plasmid in which the expression locus is not at the telomere but
more internal on the plasmid [7] (Fig. S1).
Construction of the reconstituted strain (Vmp+R)
Since the location near the telomere of lp28-1 may be important
for efficient switching of a new vmp gene into the expression site,
we did not believe the Vmp2 mutant could be complemented in
trans with the B. hermsii shuttle vector pBhSV2 [28]. Therefore, a
reconstituted strain was constructed by replacing the mutant
expression plasmid with a wild-type lp28-1 marked with a
gentamicin-resistance cassette (flaBp-aacC1)(Fig. 1), using a method
of plasmid incompatibility applied previously to B. burgdorferi [29–
34]. The reconstituted strain was gentamicin-resistant and
kanamycin-sensitive, and PCR analysis of the expression locus
indicated that an intact locus with a full-length vlp7 in the
expression site was present in the Vmp+R strain (data not shown).
Genomic DNA of the wild-type, Vmp2, and Vmp+R strains
was separated in a reverse-pulse-field gel, Southern blotted and
probed for vlp7, vlp36 (a silent cassette located on lp28-1) (Fig.1),
kan, and aacC1 (Fig. S2). The vlp7 probe hybridized to two plasmids
in all strains; one corresponding to the linear plasmid containing
the silent vlp7 cassette and the other to the expression plasmid
lp28-1 containing vlp7 in the expression site. The vlp36 probe
hybridized only to lp28-1 in all 3 strains. The kan probe hybridized
only to the lp28-1 plasmid in the mutant, and the aacC1 probe
hybridized only to the reconstituted strain lp28-1. Immunoblot
analysis confirmed that the wild-type and Vmp+R strains
Author Summary
Borrelia hermsii, an agent of tick-borne relapsing fever
when infecting humans, employs antigenic variation of the
variable major proteins (Vmps) to escape the host immune
response. This mechanism allows the bacteria to persist in
the blood of a mammal, which increases their potential for
acquisition by their tick vector Ornithodoros hermsi. Once
in the tick, the bacteria move from the midgut to salivary
glands where the Vmps are replaced with another major
surface protein, the variable tick protein (Vtp). We
constructed two mutants, one that was unable to produce
a Vmp (Vmp2) and another that was unable to produce
Vtp (Dvtp). The Vmp2 mutant could not reach as high
bacterial levels in the blood of mice when infected by
needle-inoculation and tick bite compared to the parent
strain, and was incapable of relapsing. The Dvtp mutant
was able to colonize ticks, but was non-infectious by tick
bite. Our study provides insight into the roles of the Vmps
and Vtp in the infectivity of B. hermsii by showing the
importance of antigenic variation for prolonging bacteria
levels in the host as well as the requirement of Vtp for
mammalian infection by the bite of its tick vector.
Antigenic Switching in B. hermsii
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produced Vlp7, whereas Vmp2 did not and produced Vtp instead
(Fig. 2).
Vmp2 mutant does not cause a relapse in mice infected
by needle inoculation
Since the Vmp2 mutant was unable to produce any Vmp, we
determined whether these spirochetes could persist in mice.
Groups of eight RML mice were inoculated with 500 wild-type,
Vmp2 or Vmp+R spirochetes and bacterial densities in the blood
were assessed for 14 days by Quantitative PCR (QPCR) (Fig. 3).
All mice inoculated with the wild-type spirochetes became infected
and relapsed. While an initial spirochetemia was detected in 5 out
of 8 mice infected with Vmp2, none of them relapsed. Among the
8 mice inoculated with Vmp+R, 7 of the animals relapsed, while
one animal (mouse 2) had no detectable spirochetemia by QPCR.
Serum samples were collected from all 24 animals at 4 weeks
post-infection, to compare the degree of antibody response the
mice produced as a result of their infection with either Vmp2,
wild-type or Vmp+R. The serum samples from mice that relapsed
during their infection (i.e. those infected with wild-type and
Vmp+R) reacted to multiple proteins (representative samples for
each group are shown in Fig. 4). In contrast, the serum samples
from mice infected with Vmp2 spirochetes reacted to very few
bands, and primarily to a single protein with a molecular mass of
Figure 1. Diagram of the lp28-1 plasmids for the wild-type, Vmp2 mutant and reconstituted Vmp+R strains. Schematic of a portion of
the B. hermsii linear plasmid lp28-1 contained in the wild-type (WT), Vmp-minus mutant (Vmp2), and reconstituted (Vmp+R) strains. A region of the
lp28-1 plasmid including the 59 end of vlp7, Upstream Homology Sequence (UHS), promoter (P) and ribosome binding site (rbs), T-rich region, and
proximal inverted repeat was replaced with the flgBp-kan cassette to construct the Vmp2 strain. DHS = Downstream Homology Sequence.
Arrowheads with numbers indicate primer number and location. Arrows oriented toward each other indicate inverted repeats that coincide with the
stems in the potential stem loop structures. ORFs in grey are plasmid replication genes. Light-shaded ORFs indicate vmp silent cassettes. Dark-shaded
ORF is the vmp in the expression site (vlp7). Restriction sites for Southern blot analysis are indicated on the Vmp2 plasmid. The reconstituted strain
Vmp+R has the wild-type lp28-1 containing the flaBp-aacC1 cassette.
doi:10.1371/journal.ppat.1004056.g001
Figure 2. The Vmp2 mutant B. hermsii produces Vtp but not
Vlp7. Coomassie-stained PAGE gel of whole-cell lysates of the wild-
type (WT), Vmp2 mutant, and reconstituted (Vmp+R) strains (left panel)
and immunoblots probed with anti-Vlp7 (middle panel) and anti-Vtp
(right panel) monoclonal antibodies show that the wild-type and
reconstituted strains produced Vlp7 and the mutant produced Vtp.
Molecular mass standards are shown at left in kDa.
doi:10.1371/journal.ppat.1004056.g002
Antigenic Switching in B. hermsii
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,20 kDa (Fig. 4), which was identified as Vtp in additional blots
(data not shown). The serum from the Vmp+R-infected mouse #2
that had no detectable spirochetemia (Fig. 3) also had no
serological response, confirming it was not infected (data not
shown).
Vmp2 mutant colonizes ticks like wild-type spirochetes
Ticks were infected with the wild-type, Vmp2, or Vmp+R
strains to confirm the spirochetes’ ability to colonize the tick and
move into the salivary glands. An RML mouse was first inoculated
with 500 spirochetes of one of the strains and monitored by
microscopy for peak spirochetemia. On day 4 the mice inoculated
with wild-type and Vmp+R strains had high bacterial densities in
the blood, at which time cohorts of O. hermsi ticks were fed on the
mice and became infected. After 9 days spirochetes were still
undetectable in the mouse inoculated with Vmp2, therefore
another mouse was inoculated with 1.56108 spirochetes. The
following day a high density of spirochetes in the blood was
observed and a cohort of ticks was fed on the mouse. The quantity
of bacteria in the blood was determined by QPCR with blood
taken from the mice prior to tick feeding. The three mice used to
infect the ticks with wild-type, Vmp2, and Vmp+R spirochetes had
bacterial densities of 4.56107, 1.66108, and 2.16107cells/ml of
blood, respectively.
Six ticks from each of the three groups were dissected 98–105
days after the ticks had fed and subsequently molted. Double-
labeled IFA examinations demonstrated that all 18 ticks were
infected with comparable numbers of spirochetes, which in the
salivary glands produced Vtp (data not shown). Therefore, the
inability of B. hermsii to make a Vmp did not prevent the
spirochetes from colonizing the tick salivary glands.
Figure 3. The vmp expression site is required for B. hermsii to relapse in mice following needle-inoculation. RML mice were injected ip
with 500 spirochetes of the wild-type (WT), Vmp2 mutant (Vmp2), or reconstituted (Vmp+R) strains. Mice 1–4 were sampled on days 1–14 and mice
5–8 sampled on days 2–14 post-infection and the numbers of spirochetes per ml of blood were determined by QPCR. Each plot represents the data
from an individual mouse. The lack of a detectable relapse spirochetemia in the mice infected with the Vmp2 mutant compared to the WT and Vmp+
R strains was statistically significant (Fisher’s Exact Test, P = 0.0001).
doi:10.1371/journal.ppat.1004056.g003
Figure 4. Mice inoculated with the Vmp2 mutant B. hermsii have
a reduced serological response to infection. Whole-cell lysates of
wild-type spirochetes were separated by PAGE, transferred to
nitrocellulose membranes and analyzed with mouse serum (diluted
1:500) collected at 4 weeks post infection. Two mice with representative
reactivity from each group (WT, Vmp2 or Vmp+R) of eight mice infected
by needle inoculation are shown. Molecular mass standards are shown
at left. The individual mouse number is indicated on the bottom of each
panel.
doi:10.1371/journal.ppat.1004056.g004
Antigenic Switching in B. hermsii
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Vmp2 mutant does not cause a relapse in mice infected
by tick transmission
To test if the Vmp2 mutant can cause a relapse when
transmitted by tick bite, four RML mice were each fed upon by
10 ticks infected with wild-type, Vmp2 or Vmp+R and monitored
for infection. Spirochete concentrations were quantified in the
blood by QPCR on days 3–14 post-feeding. All 4 mice fed upon
by ticks infected with wild-type or Vmp+R developed an initial
spirochetemia followed by a relapse (Fig. 5). In contrast, three of
the four mice fed upon by ticks infected with Vmp2 showed an
initial spirochetemia but no relapse was detected. Again, a strong
serological response was detected in the mice infected with the
wild-type or Vmp+R strains (data not shown), but the mice
infected with the Vmp2 mutant showed a much reduced
serological response, similar to what was observed with the
needle-inoculated mice. These observations suggest that the
Vmp2 mutant was likely cleared after the first spirochetemia.
Spirochetemic levels of the Vmp2 mutant in mice are
significantly reduced
Not only was the Vmp2 mutant unable to cause a relapse in the
mice, the levels of spirochetemia in the mice infected with Vmp2
were significantly reduced compared to the first spirochetemic
peaks in the mice infected with wild-type and Vmp+R, regardless
whether they were infected by needle-inoculation (Fig. 6A) or
infected by tick bite (Fig. 6B). The Vmp2 spirochetes only reached
a density as high as 104–105 cells/ml in the mouse blood, whereas
the wild-type and Vmp+R strains reached 106–108 spirochetes/ml
in the blood. This difference in the highest cell densities observed
for the wild-type and Vmp2 spirochetes was not explained by
monitoring their in vitro growth. These two strains had identical
growth curves in culture counted for five consecutive days, with
the wild-type and Vmp2 mutant spirochetes achieving cell
densities of 1.666108 and 2.886108 per ml, respectively.
Vmp2 mutant produces Vtp during its spirochetemic
peak
Since the Vmp2 mutant produced Vtp in culture, we asked
whether this protein was produced in the blood during the
spirochetemic peak. IFAs performed with monoclonal antibodies
to Vtp and Vlp7 showed that the mutant produced Vtp but not
Vlp7 in mice infected by needle inoculation (Fig. 7) or infected by
tick bite (data not shown). In all mice infected with the wild-type or
reconstituted strains, the spirochetes in the first spirochetemic peak
produced Vlp7 (Fig. 7B) but not Vtp (Fig. 7A).
Vmp2 mutant persists in SCID mice but at lower cell
densities than wild-type spirochetes
To address whether the lower cell densities and quick disappear-
ance of the Vmp2 mutant was due more to the innate immune
response than to the adaptive immune response, we infected SCID
mice with the 3 strains. Five SCID mice and 1 immunocompetent
C3H/HeSnJ mouse were inoculated i.p. with 500 wild-type, Vmp2,
or Vmp+R spirochetes and the bacterial densities in the blood were
determined by QPCR on days 1–12 post-inoculation. In the wild-
type C3H/HeSnJ mice, the spirochetes had similar spirochetemia
Figure 5. The vmp expression site is required for B. hermsii to relapse in mice infected by ticks. Ten ticks infected with either the wild-type
(WT), Vmp2 or Vmp+R strains were placed on a mouse and allowed to feed. Mice were sampled on days 3–14 post infection and the numbers of
spirochetes per ml of blood were determined by QPCR. Each plot represents the data from an individual mouse.
doi:10.1371/journal.ppat.1004056.g005
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patterns to those in RML mice. The wild-type and Vmp+R strains
produced an initial spirochetemia and a relapse, whereas the Vmp2
spirochetes were unable to relapse (Fig. 8). Also, the mutant did not
achieve as high cell densities as the wild-type and reconstituted strains
(105 versus 108, respectively). Even though the level of wild-type
spirochetes in the C3H/HeSnJ mouse never went below detection,
IFAs performed on blood smears collected on days 4 and 10
determined that 100% of the spirochetes produced Vlp7 on day 4 in
contrast to 0% on day 10, indicating a switch had occurred in this
mouse and a clearance was missed in the sampling times. All 15
SCID mice remained persistently infected with the 3 strains (Fig. 8),
although the wild-type and Vmp+R spirochetes achieved cell densities
7 times greater than the Vmp2 spirochetes at the peak spirochetemia
(Fig. 9A). The mutant reached densities of 107 cells/ml whereas wild-
type and reconstituted strains reached densities of 108 cells/ml. The
level of spirochetemia of the Vmp2 mutant was considerably higher
in SCID mice versus wild-type mice. However, throughout the
infection, the mutant spirochete concentrations were consistently
lower than the wild-type or Vmp+R spirochetes. For example, on day
8 (Fig. 9B), when the concentration of spirochetes in the blood of
SCID mice appeared to have leveled, the wild-type densities were 28
times greater than the Vmp2 mutant with an average of 5.46107
versus 1.96106 cells/ml, respectively; Vmp+R was 17 times more
abundant than Vmp2 with an average of 3.36107 cells/ml. IFAs
performed on blood smears collected on day 12 from SCID mice
showed that 100% of Vmp2 spirochetes were producing Vtp. In
wild-type and Vmp+R spirochetes, 34–54% and 12–87%, respec-
tively, were still producing Vlp7 on day 12 compared to day 3 when
90–100% were producing Vlp7. Also, on day 12 the SCID mice
began showing signs of illness and the experiments were terminated.
These observations show that the wild-type and reconstituted strains
switched the vmp in the expression site without an acquired immune
response in the host. In contrast, the Vmp2 mutant that was unable
to produce a Vmp continued to produce Vtp.
Vtp-minus mutant colonizes ticks but is not infectious by
tick bite
When wild-type spirochetes are acquired by a feeding tick,
the bacteria gradually down-regulate bloodstream Vmps and
up-regulate Vtp. During persistent infection in the tick salivary
glands, the spirochetes exclusively produce Vtp but quickly switch
back to the Vmp phenotype when reintroduced to mammalian
blood. Given the rapid temporal switch of B. hermsii from Vtp to
Vlp7 during mammalian infection by tick-bite [23], and the
ongoing production of Vtp by the Vmp2 mutant shown above, we
tested an isogenic strain of the spirochete in which vtp was deleted
(Dvtp)(Fig. 10, modified from Battisti et al.) [28], which rendered
the spirochete unable to produce Vtp (Fig. 11). Synthesis of Vtp
during persistent infection of the tick salivary glands suggested that
this protein might be required by B. hermsii for migration to the
salivary glands, stable tick infection, or initial colonization in
mammals. To test these hypotheses, we used genetically
transformed spirochetes described previously [28], in which the
vtp gene was inactivated (Dvtp) in B. hermsii and the mutant
reconstituted with the wild-type vtp gene (vtp+R). Battisti and
colleagues previously showed that the Dvtp mutant remained
infectious in mice by needle inoculation [28], as these spirochetes
continued to produce bloodstream Vmps in vitro. In this study we
compared these isogenic spirochetes with wild-type B. hermsii in
experimental infections with O. hermsi ticks and mice.
Ticks were infected with wild-type, Dvtp, or vtp+R B. hermsii by
feeding them on bacteremic mice and were examined by
microscopy for spirochetes producing Vtp in the midgut and
salivary glands at various times after their acquisition (Table 1). No
wild-type B. hermsii were detected in the salivary glands on day 7,
and only 1 of 5 ticks had a low level infection in the glands on day
14. By day 21, all ticks had salivary gland infections but only 6.8%
of the wild-type spirochetes in these tissues were producing Vtp.
During the ensuing months, however, over 90% of the spirochetes
became Vtp+, decreasing to 76% by day 448.
Ticks infected with Dvtp B. hermsii were examined 7 to 443 days
after feeding (Table 1). These spirochetes also disseminated from
the midgut to the salivary glands and persisted in these tissues out
to 443 days after tick feeding. However, none of 1,466 and 1,872
mutant spirochetes observed in the salivary glands and midgut,
respectively, was Vtp+. These results demonstrate that the
synthesis of Vtp was not required for B. hermsii to escape the tick’s
midgut or to colonize and persist in the salivary glands.
Additional ticks were infected with the reconstituted vtp+R
spirochetes. These ticks were dissected 49 days after feeding and
spirochetes in the midgut and salivary glands were examined for
Vtp (Table 1). Like the wild-type spirochetes, the vtp+R B. hermsii
also disseminated from the midgut to the salivary glands and up-
regulated the synthesis of Vtp during tick infection.
Spirochetes were also examined in a few ticks from day 7 to 116
days after infection for the presence of Vlp7, which was the Vmp
produced when acquired by the ticks (5 ticks infected with wild-
type and 6 ticks infected with Dvtp mutant spirochetes) (Table 2).
No spirochetes were Vlp7+ in the salivary glands (0/254) while
63% (284/452) of spirochetes were Vlp7+ in the midgut. For both
B. hermsii strains these results confirmed our earlier observations
regarding the partitioning of phenotypes, with no spirochetes
producing bloodstream Vmps in the tick salivary glands [23].
Transmission experiments were performed with ticks infected
with wild-type, Dvtp mutant or vtp+R spirochetes on days ranging
from 66 to 386 after their previous infectious blood meal. All mice
(100%) fed upon by ticks infected with wild-type or vtp+R B. hermsii
developed spirochetemias detectable by microscopy and were later
seropositive (Table 3). In contrast, none of the mice fed upon by
the Dvtp B. hermsii-infected ticks became spirochetemic or
seroconverted. Immunological staining of the spirochetes in the
blood smears from the 10 mice that developed detectable
spirochetemias, identified the bacteria as serotype 7, which again
Figure 6. The spirochetemic levels of the Vmp2 mutant are
significantly less than wild-type and Vmp+R strains. Each data
point represents the number of spirochetes per ml of blood for an
individual mouse during the first initial peak in needle-inoculated RML
mice (n = 7 for Wild-type and Vmp+R, n = 5 for Vmp2) (A). First
spirochetemic peak densities in RML mice infected by tick bite (10 ticks/
mouse; n = 4 for Wild-type and Vmp+R, n = 3 for the Vmp2) (B). These
data were taken from the first peaks shown in Fig. 3 & 5. The
spirochetemic levels of Vmp2 mutant were significantly less than the
levels of wild-type and Vmp+R strains (*** P , 0.0001). Statistical
significance was determined by one-way ANOVA with the Tukey’s
Multiple Comparison Test.
doi:10.1371/journal.ppat.1004056.g006
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was the same serotype that the ticks were infected with previously.
These results demonstrate that Vtp is required for mammalian
infectivity of B. hermsii by tick bite.
Discussion
In this study, we examined the necessity of switching between
Vmps or Vtp during the life cycle of B. hermsii. Evading the host’s
humoral immune response would allow repeated high levels of
bacteremia, which clearly increases the potential for these
spirochetes to be acquired by their fast-feeding tick vector that
ingests very small volumes of blood [15,35]. However, the
adaptive significance of the spirochete’s switch from a bloodstream
Vmp to Vtp while in the tick for transmission back to a mammal is
far less intuitive. The switch is even more perplexing, given that
the spirochetes retain the same Vmp gene in the expression site
while infecting ticks, and that spirochetes producing Vmps and not
Vtp are infectious when passaged from one mouse to another by
needle inoculation of infected blood [4]. Phenotypes of the vmp and
vtp deletion mutants of B. hermsii shed light on the biological
significance of replacing a bloodstream Vmp with Vtp when B.
hermsii resides in ticks.
Infection in immunocompetent mice
The B. hermsii Vmp2 mutant was attenuated in immunocompe-
tent mice when inoculated by needle or delivered naturally by tick-
bite. The attenuation was characterized by 1) fewer mice with a
detectable spirochetemia, 2) reduced cell density during the initial
spirochetemia, and 3) no mice with a detectable relapse. The much
reduced antibody response observed after infection with the Vmp2
mutant was consistent with the transient, low-level spirochetemia.
The inability of the B. hermsii Vmp2 mutant to relapse in
immunocompetent mice was our predicted outcome for these
Figure 7. The Vmp2 mutant B. hermsii produces Vtp during its spirochetemia. Spirochetes in blood smears collected from mice infected
with the wild-type (WT), Vmp2 mutant or reconstituted (Vmp+R) strains were double-labeled with a rabbit anti-B. hermsii hyper-immune serum and a
mouse anti-Vtp (A) or anti-Vlp7 (B) monoclonal antibody. The wild-type and Vmp+R spirochetes produced Vlp7 during the first spirochetemic peak in
mice while the Vmp2 mutant produced Vtp.
doi:10.1371/journal.ppat.1004056.g007
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infection experiments. Our study is the first to identify host-
associated phenotypes in the life cycle of a relapsing fever
spirochete by genetically inactivating specific gene targets. Lyme
disease spirochetes Borrelia burgdorferi also contain an elaborate
mechanism for antigenic variation first described by Zhang and
colleagues [36]. The expression site is telomeric on linear plasmid
lp28-1 and contains a vmp-like sequence, designated vlsE, which
has highest sequence similarity to vlp17 of B. hermsii. Upstream of
the vlsE expression site are 15 silent cassettes that contain internal
variable sequences, portions of which recombine into vlsE with the
potential to create millions of unique vlsE alleles [36]. One striking
difference between these two species of spirochetes is that the vlsE
locus in B. burgdorferi produces an extremely high number of
antigenic variants in a single host at one time, such that the
spirochetes have the ability to continually evade the host’s humoral
immune response and persist throughout the life of the infected
animal [37]. Experimental infections with B. burgdorferi show that
laboratory mice remained infected for a year [38,39] to 16 months
after inoculation until the animals were euthanized [40]. Infected
white-footed mice (Peromyscus leucopus), a primary reservoir for B.
burgdorferi in eastern North America [41,42], continually infected
new cohorts of ticks in the laboratory for many months [43], and
are likely capable of doing so for their entire life once infected.
Figure 8. The Vmp2 mutant B. hermsii persists in the blood of SCID mice. Five SCID mice and 1 wild-type mouse with the same genetic
background (C3H/HeSnJ) were injected ip with 500 spirochetes of wild-type (WT), Vmp2, or reconstituted (Vmp+R) strains. Mice were sampled on
days 1–12 post-infection and the numbers of spirochetes/ ml of blood were determined by QPCR. Growth rates of the three strains in SCID mice
during three consecutive days of exponential growth were not significantly different based on linear regression analysis of the slopes (P = 0.1129).
doi:10.1371/journal.ppat.1004056.g008
Figure 9. The Vmp2 mutant B. hermsii has reduced spiroche-
temic levels in the blood of SCID mice. Each data point represents
the number of spirochetes per ml of blood for an individual mouse
during the first spirochetemic peak (A) and later during a persistent
infection (day 8) in SCID mice (B) (n = 5 mice for each strain). These data
were taken from two time points presented in Fig. 8. The spirochetemic
levels of Vmp2 mutant were significantly less than the wild-type (WT)
and reconstituted (Vmp+R) strains (*** P , 0.0001, *P , 0.05). Statistical
significance was determined by one-way ANOVA with the Tukey’s
Multiple Comparison Test.
doi:10.1371/journal.ppat.1004056.g009
Figure 10. Diagram of the vtp locus in the wild-type, Dvtp
mutant and reconstituted strain vtp+R. The vtp gene in the wild-
type (WT) B. hermsii DAH was inactivated by deleting most of the gene
and replacing it with the flgBp-kan cassette by homologous recombi-
nation, creating the Dvtp mutant. The reconstituted strain (vtp+R) was
constructed by replacing the Dvtp mutation with the flaBp-aacC1
cassette next to an intact vtp gene, also by homologous recombination.
Details were described previously [28].
doi:10.1371/journal.ppat.1004056.g010
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Evidence for the possible role of vlsE for persistent infection of B.
burgdorferi in mammals was demonstrated with clones lacking lp28-
1, the plasmid encoding this locus, which had a reduced
(‘‘intermediate’’) infectivity in mice [30,36,44]. Subsequently,
Bankhead and Chaconas [45] demonstrated that clones of B.
burgdorferi lacking the vlsE locus via targeted genetic inactivation
were present in blood of mice on days 4 and 7 postinoculation but
were no longer isolatable from any mouse tissues by 3 weeks. That
study demonstrated the essential role of the vlsE locus for B.
burgdorferi to persistently infect mammals. Thus, both B. hermsii and
B. burgdorferi have linear plasmid-encoded expression loci that are
essential for each spirochete’s production of antigenic variants to
persist for either shorter (weeks to a few months) or longer (life of
the host) periods of time, respectively.
Another objective of our study was to elucidate additional
functions that the Vmps might provide the spirochete other than
to evade the host’s humoral immune response. During the first
detectable peak in spirochetemia, the Vmp2 mutant achieved a
significantly lower mean cell density in the blood at approximately
105 spirochetes per ml whereas wild-type and reconstituted strains
were more abundant at 107 to 108 spirochetes per ml (Fig. 6).
Because peaks in spirochetemia of the mutant coincided with the
same days for the peaks in spirochetemia for mice infected with the
wild-type and reconstituted spirochetes (Fig. 3 & 5), we believe that
the differences we observed in spirochete densities were not due to
different growth rates but rather a reduced fitness of the Vmp2
mutant. This hypothesis was supported by nearly identical growth
curves of the wild-type and Vmp2 mutant spirochetes when grown
in culture and SCID mice.
In the normal transmission cycle, B. hermsii down-regulates the
bloodstream Vmp following its acquisition by ticks, and up-
regulates Vtp while persistently infecting the tick’s salivary glands
(this report and [23]). During the tick’s subsequent feeding, Vtp-
positive spirochetes are transmitted to the mammalian host, but by
3 to 5 days post infection (when the spirochetes are abundant
enough to be visualized by microscopy), the spirochetes no longer
make Vtp and have switched back to the same bloodstream Vmp
that the spirochetes were making when previously acquired from
the infected host [23]. In our infection experiments with
immunocompetent mice, the phenotypes of wild-type and Vmp+R
reconstituted spirochetes were as expected; borreliae in the first
spirochetemia produced Vlp7 but not Vtp (Fig. 7). However, the
Vmp2 mutant remained Vtp-positive during its initial and only
detectable peak of infection in immunocompetent mice. Might the
prolonged synthesis of Vtp, and the spirochetes’ inability to switch
back to Vlp7 confer a disadvantage during growth in vivo,
separate from evading an antibody response directed to Vtp by the
infected host?
The presence of Vtp-positive cells in the Vmp2 mutant
population during early infection in immunocompetent mice was
not totally unexpected. Barbour et al. [26] demonstrated that the
synthesis of Vtp is controlled at the level of transcription, and
when a vmp gene is transcribed in vitro, vtp is not. The reverse is
also true such that B. hermsii cells express a vmp or vtp, but not both
genes simultaneously [26]. Therefore, we hypothesized that our B.
hermsii Vmp2 mutant would constitutively produce Vtp, which is
what we observed.
The spirochetemia plots displayed by our Vmp2 mutant that
produced Vtp showed an initial reduced cell density and no
relapse (Fig. 3 & 5). This pattern of infection is strikingly similar to
the infection profiles reported by Alugupalli et al. [9], who used
the same strain of B. hermsii that we used (DAH) but after the
culture was passaged 19 times in vitro prior to inoculation in mice.
B. hermsii does not typically lose plasmids and infectivity during in
vitro cultivation [46,47] as does B. burgdorferi [44,48,49], however,
the continuous growth in vitro appears to attenuate B. hermsii
similar to what we observed with the low passaged Vmp2 mutant.
Although Alugupalli et al. [9] did not identify the serotype of B.
hermsii after 19 passages, we assume that the majority, if not all, of
the spirochetes had switched to Vtp (previously named ‘‘culture
type’’ and Serotype C [4,50] and pIc, VmpC, and Vsp33 [25,51]).
Barbour et al. [26] also observed that two culture-derived serotype
C isolates of B. hermsii HS1 were less virulent in irradiated mice
compared to lower passaged cultures comprised of other serotypes.
One possible explanation for wild-type B. hermsii becoming
attenuated during continuous growth in culture might be the loss
of efficient regulation for switching the expression of vtp to a vmp
when spirochetes are inoculated into a mammal. Our attenuated
Vmp2/Vtp+ mutant stimulated an antibody response in the
immunocompetent mice that was restricted almost entirely to Vtp
(Fig. 4). Additionally, we have produced antibodies to purified Vtp
in rabbits that are borreliacidal to B. hermsii cells producing Vtp
(Schwan, unpublished observations). Therefore, we believe that
the Vmp2 mutant stimulated the production of neutralizing
antibodies to Vtp that quickly cleared the infection in mice.
Infection in SCID mice
The antigenically distinct serotypes of B. hermsii and other
relapsing fever spirochetes stimulate a specific IgM antibody
response produced by the host’s B1b lymphocytes, which results in
the clearance of the majority of the spirochetes from the blood
[9,10,12,52]. Rare spontaneous antigenic variants that are unique
from the infecting serotype escape the antibody-mediated killing
and are progenitors for new serotypes to repopulate the blood [4].
In the absence of a host’s antibody response, our predictions were
that the infecting serotype of B. hermsii would not be cleared and
instead maintain a persistently high cell density in the blood. Also,
with no antibody-based immune pressure to select a new serotype,
the wild-type spirochetes might not switch Vmps. Regarding our
Figure 11. The Dvtp mutant B. hermsii does not produce the
variable tick protein. Coomassie-stained PAGE gel of whole cell
lysates (top panel) of the wild-type (WT), Dvtp mutant and reconstituted
(vtp+R) strains and immunoblots probed with anti-Vlp7 (middle panel)
and anti-Vtp (bottom panel) monoclonal antibodies. All 3 strains
produced Vlp7 while the mutant did not produce the variable tick
protein (Vtp). Molecular mass standards are shown at left in kDa. *
indicates Vlp7 protein, ** indicates Vtp protein.
doi:10.1371/journal.ppat.1004056.g011
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first prediction, we observed what other investigators have
demonstrated previously; B. hermsii achieves persistently high levels
of bacteremia in irradiated, SCID or chemically-treated mice
deficient in their production of antibodies [4,9,53,54]. All three
isogenic strains of B. hermsii (wild-type, Vmp2 mutant, Vmp+R)
produced high and persistent spirochetemias in SCID mice for 12
days after needle inoculation (Fig. 8). However, immunofluores-
cent stains of the wild-type and reconstituted spirochetes
demonstrated that, while early in their infections (Day 3) nearly
100% of the spirochetes were Vlp7-positive (the infecting
serotype), by Day 12 the percentage of spirochetes that were
Vlp7-positive had dropped significantly to as low as only 12% in
one of the mice. Therefore, just as Stoenner et al. [4] observed the
spontaneous conversion to variant B. hermsii in cyclophosphamide-
treated mice and in the fortified Kelly’s medium [4], our serotype
7 spirochetes also switched to other unidentified serotypes during
infection in SCID mice.
The Vmp2 mutant showed significantly lower levels of
spirochetemia in SCID mice compared to the wild-type and
reconstituted spirochetes (Fig. 8 & 9), just as we observed with the
infections in immunocompetent mice (Fig. 3 & 5). The Vmp2
mutant remained Vtp-positive during the 12 days of infection,
unlike the wild-type and reconstituted spirochetes that switched
spontaneously from Vlp7 to other Vmps. Although the Vmp2
mutant/Vtp-positive spirochetes persisted in the absence of
antibody, these bacteria were moderately attenuated in the SCID
mice, in that they were unable to grow to the same cell densities.
Thus the Vmp2 mutant B. hermsii was less fit than wild-type and
reconstituted spirochetes even in immunodeficient mice. How
might the spirochete’s inability to produce a Vmp create a
disadvantage for their growth in vivo? Alugupalli et al. [9]
observed a reduction in the density of B. hermsii cells during
persistent infection in SCID mice as did we, and these
investigators suggested that some arm of the host’s innate
immunity might elicit some control of the spirochetemia. If such
an impact of innate immunity is involved, then possibly the Vmps
of B. hermsii offer slightly greater protection to the cells than does
Vtp.
The reduced cell density of the Vmp2 mutant in the blood also
suggests a possible growth defect in nutrient acquisition. B. hermsii
and other species of relapsing fever spirochetes have pathways for
the uptake and utilization of glycerol and purines that are absent
in Lyme disease spirochetes [55–57]. We have speculated
previously that these additional metabolic pathways in the
relapsing fever spirochetes might help these bacteria to achieve
much higher cell densities in the blood than do the Lyme disease
spirochetes [56,57]. Possibly the presence of a Vmp rather than
Vtp on the spirochete’s outer surface allows for the greater uptake
of glycerol, the salvage of purines, or the uptake of other nutrients
in the blood (while also offering some protection from the host’s
innate immunity). Another scenario might be a difference in rate
of bacterial clearance in the spleen and liver due to spirochetes
with different abundant outer surface proteins having different
affinities for binding to the cellular components of the blood. B.
hermsii cells bind to platelets and erythrocytes [53,58,59] and the
presence of Vtp rather than the bloodstream Vmps might make
the spirochetes more adherent to cells and more susceptible to
their removal in the spleen and liver [58]. While the
mechanism(s) are not known, Vmp-positive B. hermsii had an
advantage over the Vmp2 mutant/Vtp-positive cells in mice,
which suggests that the variable major proteins confer some
advantage to the spirochetes separate from contributing to a
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Vmp and VlsE production in ticks
B. hermsii and B. burgdorferi differ in their population of variants
that are present in a single host [37]. A multitude of B. burgdorferi
VlsE variants are present simultaneously in the mouse while the
vast majority of B. hermsii cells present at one time are comprised of
one serotype that produce the same Vmp [60]. Given the
importance of variation in the Vmp and VlsE antigens to prolong
mammalian infection via immune evasion, the lack of change in
these surface proteins in ticks might be expected and is what we
observed. In all acquisition and transmission events that we
monitored with wild-type and reconstituted spirochetes, O. hermsi
ticks transmitted spirochetes of the same serotype (i.e., no change
in Vmp) that they acquired during their previous blood meal.
Therefore, no recombination events occurred in the vmp expres-
sion site during infection in ticks. Additionally, many wild-type B.
hermsii no longer produced Vlp7 when in the tick midgut and no
Vlp7-positive spirochetes were found in the tick salivary glands.
When B. burgdorferi infects its tick vector Ixodes scapularis, genetic
variation in the VlsE locus also ceases and spirochetes quickly shut
down the production of the protein [61–64]. Cumulatively, these
observations demonstrate that neither wild-type B. hermsii nor B.
burgdorferi change Vmp or VlsE antigens while infecting their
respective tick vectors. Our infections with Vmp2 mutant B.
hermsii in O. hermsi also demonstrated conclusively that this
spirochete’s mechanism to vary antigenically in mammals was
not required to colonize and persist in ticks. Additionally, the
Vmp2 mutant still produced Vtp in the tick salivary glands, and
was infectious, although attenuated, in mice when subsequently
transmitted by tick bite. We are not aware of a comparable study
in which a specific vlsE2 mutant B. burgdorferi has been tested for
infectivity when transmitted by its hard tick vector.
Vtp required for infectivity by tick bite
The B. hermsii Dvtp was the second deletion mutant we examined
in the infectious cycle with ticks and mice. Previous work in our
laboratory [23] and the new time-course data presented here
(Table 1) demonstrate that wild-type B. hermsii up-regulated Vtp
synthesis in ticks and that the switch was gradual over many weeks,
as spirochetes disseminated from the midgut to salivary glands.
Over 90% of the spirochetes in the salivary glands became Vtp-
positive while relatively few bacteria that remained in the midgut
made the switch. The presence of wild-type B. hermsii in the tick
salivary glands that had not yet begun to produce Vtp suggested
this protein was not required for the spirochetes to either escape
from the midgut or colonize the salivary glands. This hypothesis
was confirmed with the Dvtp mutant, which was able to colonize
and persist in the tick salivary glands for well over a year (63 weeks)
(Table 1).
The striking phenotype of the Dvtp mutant was its loss of
infectivity when ticks infected with this spirochete fed on mice.
None of the mice exposed cumulatively to 60 ticks infected with
this mutant became spirochetemic or seroconverted, while all mice
fed upon by ticks with the wild-type (60 ticks) and reconstituted
spirochetes (34 ticks) became infected. Therefore, synthesis of Vtp
by B. hermsii while infecting the salivary glands is essential for
spirochete infectivity in mice when delivered by tick bite. Our
results are strikingly similar to studies that have examined the role
of the Vtp orthologous protein, OspC, produced by B. burgdorferi
during its infectious cycle in ticks and mammals. This major outer
surface protein is not produced by spirochetes in the midgut of
unfed Ixodes scapularis ticks. But by 48 hr after ticks have attached to
a warm-blooded mammal and begun to feed, spirochetes turn on
the synthesis of OspC [65–68]. Production of OspC is tightly
coordinated with the transmission of B. burgdorferi while ticks feed,
however, this protein is not required for spirochetes to escape the
midgut and penetrate the salivary glands [69]. However, OspC is
essential for B. burgdorferi to be infectious in mammals via tick bite
[69], just as we have observed with our Dvtp mutant. Thus, both B.
hermsii and B. burgdorferi require the synthesis of the orthologous
proteins Vtp and OspC, respectively, to infect mammals by tick
bite, yet the essential roles provided by these proteins are
unknown.
The mechanism underlying the regulatory control of OspC
synthesis by B. burgdorferi during tick feeding has received much
attention and was nicely reviewed by Samuels [70]. From the
initial observations that an increase in temperature and the tick’s
blood meal stimulate the upregulation of OspC [65,66,71], the
production of this protein and many others requires the Rrp2-
RpoN-RpoS cascade. Little is yet known about the regulatory
control of Vtp by B. hermsii but two interesting differences are
apparent. First, while an increase in temperature during in vitro
growth stimulates B. burgdorferi to make OspC, the opposite is true
for B. hermsii, which turns on Vtp when grown in culture at lower
temperatures and following acquisition from a warm-blooded
mammal to the cold-blooded tick [23]. These opposite affects of
temperature may relate to bacterial growth rate as was recently
proposed for B. burgdorferi [72]. We have recently released the
genomes of four isolates of B. hermsii, which are available in
GenBank of the National Center for Biotechnology Information.
These data include the chromosomal sequence of the isolate B.
hermsii DAH (CP000048) we used in our present study, as well as B.
hermsii YOR (CP004146), B. hermsii MTW (CP005680) and B.
hermsii YTB (CP005706). While these spirochetes contain most
genes of the two component regulatory response-RpoS cascade,
none of them contains an intact RpoN gene. Therefore,
comparative differences in how B. burgdorferi and B. hermsii control
the synthesis of OspC and Vtp, respectively, await further
investigation.
Interestingly, the reciprocal expression of a vmp and vtp by B.
hermsii while grown in vitro, in which single cells produce either a
Vmp or Vtp, but not both [26] was not what we observed in the
Table 3. Vtp mutant is non-infectious to mice by tick bite.
Strain No. Mice No. Spirochetemica No. Seropositiveb % Infected 1st Serotype
Wild-type 6 6 6 100 7
Dvtpc 6 0 0 0 NA
vtp+R 4 4 4 100 7
aNo. of mice spirochetemic within 10 days post-infection.
bNo. of mice seropositive examined 3–4 months post-infection.
cThe lack of infection by the mutant compared to the wild-type and reconstituted strains is significantly different (Fisher’s Exact Test, P = 0.0001).
doi:10.1371/journal.ppat.1004056.t003
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salivary glands of infected ticks. Our double-label IFA stains
demonstrated that spirochetes never produced Vlp7 in tick salivary
glands regardless of the strain examined. The analysis of the Dvtp
mutant showed that these B. hermsii cells lacked both Vtp and a
Vmp in the salivary glands and were not infectious by tick bite.
Recently, Marcisisin and colleagues described such a B. hermsii
variant that arose spontaneously in the type strain HS1, which
after years of continuous in vitro cultivation no longer produced a
Vmp or Vtp [73]. This spirochete was no longer infectious in mice
by needle inoculation but was used to hyperimmunize animals to
generate antibodies to other surface proteins. Our Dvtp mutant
remained infectious by needle inoculation, which we assume was
due to the production of Vlp7 during growth in vitro.
Our B. hermsii Vmp2 mutant constitutively produced Vtp while
infecting mice, but the strain was attenuated and cleared by mice
capable of producing an antibody response to infection. Addi-
tionally, Vtp was required for spirochetes to be infectious by tick
bite but the constitutive presence of this protein made the
spirochetes less fit. Among the approximately 75 isolates of B.
hermsii that we have established during the last 25 years from
human patients, wild mammals and ticks, we have identified 9
antigenically distinct groups of Vtp proteins, which between the
groups share only 60 to 75% amino acid identity, yet within each
group the sequences are identical or nearly so [27](unpublished
data). This polymorphism in Vtp suggests there is a selective
pressure driven by the natural hosts’ immune response, which has
been suggested to be the driving force for polymorphism of OspC
types found among isolates of B. burgdorferi [74,75].
B. hermsii spirochetes quickly switch from Vtp to a Vmp after
transmission by tick bite. While we do not know the function that
makes Vtp essential for vector-borne infection, we suggest the
following speculative model for the adaptive value for this
spirochete to enter a host body with one antigenic type (Vtp)
and then quickly switch to another (Vmp). If spirochetes first
colonize the blood stream of the host while producing Vtp, which
starts to stimulate an IgM antibody response to this surface
protein, but then quickly change to Vmp-producing cells via the
switch between two promoters [26], the infecting population may
have a growth advantage that allows the cells to achieve a higher
cell density. B. hermsii cells producing Vtp upon entry into the host
might temporarily divert the acquired immune response to a
surface protein that quickly disappears. This could allow
spirochetes to establish the infection, replicate, switch and possibly
achieve a higher cell density in the blood before being cleared. An
adaptation that results in a delay in the host’s immune response to
clear the infecting serotype would confer an advantage for their
acquisition by tick bite by allowing more spirochetes to circulate in
the blood at a higher cell density. We hope to test this hypothesis
in the future with B. hermsii that produce a bloodstream Vmp in
place of Vtp when transmitted by ticks to mammals.
Materials and Methods
Ethics statement
The Rocky Mountain Laboratories, NIAID, NIH, Animal Care
and Use Committee approved study protocols #2009-32, #2009-
87, #2012-29 and #2012-70 for the feeding of ticks on mice,
infecting mice with spirochetes, and the isolation of spirochetes from
mouse blood samples. All work in our study was conducted adhering
to the institution’s guidelines for animal husbandry, and followed the
guidelines and basic principals in the Public Health Service Policy on
Humane Care and Use of Laboratory Animals, and the Guide for
the Care and Use of Laboratory Animals, United States Institute of
Laboratory Animal Resources, National Research Council.
Bacterial strains and growth conditions
B hermsii DAH 2E7 was cloned by limiting dilution in liquid
mBSK-c medium from the low-passaged non-clonal isolate DAH
[18,27,28,76]. Although much of the studies regarding antigenic
variation in B. hermsii have been done with isolate HS1, the DAH
isolate is nearly identical to HS1, as shown by multi-locus
sequencing [27] and plasmid sequences containing the silent vmp
genes [16,18]. The vmp gene in the expression site of B. hermsii
DAH 2E7 was amplified and sequenced with primers pro and tel
(Table S1) as described [16,21,77] and was determined to be vlp7.
Between vlp7 and the telomere is a vsp26 pseudogene, which is
silent in B. hermsii HS1 [16,21,77]. Transformants of low-passaged
DAH 2E7 were selected with kanamycin at 100 mg/ml or with
gentamicin at 20 mg/ml in mBSK-c containing 12% rabbit serum
(Pel-Freez, Rogers, AR) [28,78], incubated at 35uC and 5% CO2
and 3% O2 in a Forma Series II Water Jacket CO2 incubator
(Thermo Fisher Scientific, Inc., Waltham, MA) with the caps
loosely attached on the culture tubes. Clones were isolated by
limiting dilution in liquid medium as described [28]. Escherichia coli
TOP10 (Invitrogen, Carlsbad, CA) was used for the generation of
constructs and grown in Luria broth or agar plates with
kanamycin (50 mg/ml) or gentamicin (5 mg/ml).
Genomic DNA isolation from B. hermsii
Genomic DNA of B. hermsii used for PCR was isolated from
5 ml cultures using the Wizard Genomic DNA Kit (Promega,
Madison, Wi) following the instructions for Gram-negative
bacteria. Genomic DNA of B. hermsii used for reverse-pulse-field
gels or transformations was extracted from 100 ml cultures or as
minipreps from 5 ml cultures as previously described [79].
Southern blot analysis
Undigested genomic DNA was resolved by reverse-pulse-field
gel electrophoresis as previously described [27] and genomic DNA
(2 mg) digested with restriction enzymes was electrophoresed in a
1% agarose gel in TAE. DNA was transferred onto a Magna-
Graph Nylon Membrane (Osmonics, Inc., Minnetonka, MN), and
hybridized as previously described [80] with the exception that
higher stringency washes were done with 0.1X SSC-0.1%SDS.
Blots were prehybridized for 6 hr at 65uC and hybridized
overnight at 55uC with probes to the kanamycin-resistance gene
kan and the gentamicin-resistance gene aacC1 (gent) [28], or at
65uC with probes to vlp7 and vlp36 (for detection of the plasmid
lp28-1).
Hybridization probes were produced with the PCR DIG Probe
Synthesis Kit (Roche Applied Science, Indianapolis, IN) following
the manufacturer’s instructions. Wild-type B. hermsii genomic
DNA was used as template for the vlp7 and vlp36 probes. Probes
for kan and gent were PCR-amplified from pTABhFlgB-Kan and
pTABhFlaB-Gent, respectively [28]. PCR amplification of the
probes consisted of an initial denaturation at 94uC for 5 min; 35
cycles of 94uC for 30 sec, 60uC for 30 sec, 72uC for 2 min; and a
final extension at 72uC for 7 min. The primers used to amplify the
probes were: 15 and 16 for vlp7, 24 and 39 for vlp36, 42 and 43 for
kan, and 40 and 41 for the gentamicin-resistance gene, aacC1
(Table S1). The probe for vlp7 lay in the truncated fragment of vlp7
that remained at the expression site in the Vmp-minus mutant,
Vmp2.
Construction of the Vmp-minus mutant (Vmp2) and
reconstituted (Vmp+R) strains
All PCR fragments larger than 1.5 kb were amplified with the
Expand Long Template PCR System (Roche) while PCR products
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smaller than 1.5 kb were amplified with Go-Taq Flexi DNA
polymerase (Promega) according to manufacturer’s instructions.
PCR products and restriction-digested vectors were purified by the
Qiagen PCR Purification Kit or Gel Extraction Kit (Qiagen Inc.,
Valencia, CA). Restriction enzymes and ligase were purchased
from New England Biolabs, Inc. (Ipswich, MA). All intermediate
products in plasmid constructions were sequenced using primers
listed in Table S1.
Plasmid pExpKO (Fig. S3A) was constructed to delete the
regulatory region of the vmp expression site and replace it with a
kanamycin-resistance cassette by homologous recombination.
Construction of pExpKO was done in three sequential steps.
First, a 2.1 kb fragment upstream of the region of DNA to be
deleted (Fig. 1, S3A) was amplified with primers 3 and 4 (Fig. 1,
S3A, Table S1) from B. hermsii DAH SpeI-digested genomic DNA
and cloned into the TOPO-XL vector (Invitrogen). Second, the
kanamycin-resistance gene fused to the B. hermsii flgB promoter
(flgBp-kan) was amplified from pTABhFlgB-Kan [28] with primers
5 and 6 (Table S1), digested with XhoI and SpeI, and ligated next to
the upstream flanking region in the TOPO-XL plasmid digested
with AvrII and XhoI. Finally, a 1.2 kb fragment downstream of the
region of DNA to be deleted that contained the 3’ portion of vlp7
and the 59 portion of the pseudogene vsp26 was amplified with
primers 7 and 8 (Fig. 1, S3A, Table S1). The fragment was
digested with SalI and XbaI and ligated into the vector cut with
XhoI and XbaI, yielding pExpKO (Fig. S3A). The construct was
sequenced with primers 7–18 (Table S1) to confirm that no
mutations in the flanking DNA had been introduced. The plasmid
was transformed into wild-type B. hermsii DAH 2E7 (Fig. 1, WT)
and the Vmp-minus mutant, Vmp2 (Fig. 1), was selected with
kanamycin-supplemented medium (see below for further details).
Mutants were confirmed by PCR with primer pairs 19/20 and
21/22, where one primer is within the kan gene and the other
outside of the flanking DNA cloned into pExpKO.
The reconstituted strain, Vmp+R, was constructed by replacing
the mutant lp28-1 expression plasmid with a wild-type copy of
lp28-1 marked with a gentamicin-resistance cassette (Fig. 1). This
required a two-step process: first construct a strain with a marked
wild-type copy of the plasmid, and then use genomic DNA from
this strain to transform the Vmp2 mutant. For the first construct a
3 kb fragment of lp28-1 was PCR-amplified from genomic B.
hermsii DNA with primers 23 and 24 (Table S1, Fig. 1, S3B), and
cloned into a TOPO-XL vector. The resulting plasmid was
amplified by inverse PCR with the primers 25 and 26 (Table S1,
Fig. S3B) to introduce restriction sites, and then digested with AvrII
and XmaI. The gentamicin-resistance cassette (flaBp-aacC1) was
amplified from pTABhFlaB-Gent [28] with primers 27 and 28
(Table S1), digested with XmaI and SpeI, and ligated into the vector
and sequenced with primers 23–34 (Table S1). The resulting
pLp28-1G (Fig. S3B) was transformed (see below) into the wild-
type B. hermsii DAH 2E7 and transformants were selected with
gentamicin. The marked wild-type plasmid contained the genta-
micin-resistance cassette inserted between the pf50 and tra genes
on lp28-1 and created a 71bp deletion in a non-coding region of
DNA in the lp28-1 plasmid. Insertion of the flaBp-aacC1 into lp28-
1 was confirmed by PCR with primer pairs 35/37 and 36/38
(Table S1), where one primer was located within the gentamicin–
resistance cassette and the other was located on lp28-1 outside of
the region cloned into pLp28-1G. Genomic DNA was isolated
from this strain and transformed into Vmp2 mutant strain (see
below). The reconstituted mutants were selected with gentamicin,
cloned by limiting dilution, and the clones were screened for loss of
kanamycin resistance.
Construction of the Vtp-minus mutant (Dvtp) and
reconstituted (vtp+R) strains
The same clone (2E7) of B. hermsii DAH that was used to
produce the Vmp2 mutant was also used to produce the Dvtp
mutant and its reconstituted strain. The methods for constructing
Dvtp and vtp+R were presented previously [28].
Transformation of B. hermsii
Competent B. hermsii cells were electroporated with 25 mg
plasmid or genomic DNA as described by Battisti et al. [28] with
the following changes for the Vmp2 and Vmp+R strains: The EPS
buffer contained potassium phosphate (0.27 M sucrose, 15% w/v
glycerol, 2.43 mM K2HPO4, 0.57 mM KH2PO4, pH 7.4) and was
used at 4uC instead of RT, and the cultures were grown in a low
O2 (3%) incubator. After 4–7 days in antibiotic selection, 1 ml of
the culture was passed into 5 ml fresh medium with antibiotics,
allowed to grow for 3 days, and then cloned by limiting dilution.
Immunoblots and serology
B. hermsii whole cell lysates were prepared as previously
described [81] and electrophoresed in a 12% Tris-Glycine gel
(Life Technologies, Carlsbad, CA). Proteins were transferred onto
a nitrocellulose membrane in the BioRad transblotter (Bio-Rad
Laboratories, Hercules, CA) with transfer buffer (11.25 mM
NaPO4-dibasic, 3.75 mM NaPO4-monobasic). Membranes were
blocked overnight in TBS-T (25 mM Tris, 150 mM NaCl, 0.1%
Tween-20 pH 7.4) containing 5% powdered milk. Membranes
were incubated with convalescent serum samples from infected
mice (diluted 1:500), mouse anti-Vtp monoclonal antibody H4825
[25] (diluted 1:50), or mouse anti-Vlp7 monoclonal antibody
H9326 [82] (diluted 1:50) in TBS-T with 5% milk for 1 hr.
Membranes were washed 3 times for 10 min each with TBS-T
then incubated with HRP-rec-protein A 1:5000 (Invitrogen) in
TBS-T with 5% milk for 1 hr. Membranes were washed 3 times
for 10 min with TBS-T and bound antibodies were detected with
the SuperSignal West Pico Chemiluminescent Substrate (Thermo
Fisher Scientific, Inc.) and visualized on film.
QPCR quantification of spirochetes in the blood of
infected mice
Adult female RML mice were from a closed colony at the
Rocky Mountain Laboratories that originated from outbred Swiss-
Webster mice. Severe combined immune deficiency (SCID) mice
C3SnSmn.CB17-Prkdcscid/J and the background strain C3H/
HeSnJ mice were purchased from The Jackson Laboratory. SCID
mice were housed in isolator cages.
Mice were inoculated with 500 spirochetes by intraperitoneal
(i.p.) injection or fed upon by 10 O. hermsi ticks infected with the
wild-type, Vmp2 mutant, or Vmp+R reconstituted strains (tick-
infections described below). The number of spirochetes in blood
was quantified by QPCR as described by McCoy et al. [35].
Briefly, blood was collected from the mice by nicking the tip of the
tail and expressing blood from the tail vein onto a slide. A 5 ml
drop of blood was placed into 95 ml of SideStep Lysis and
Stabilization Buffer (Agilent Technologies, Santa Clara, CA) in
duplicate and stored at –80uC. When all samples were collected,
the lysed cells were thawed and diluted 1:10 in sterile distilled
water and 3 ml were used as template in triplicate in QPCR using
the Stratagene Brilliant II QPCR Master Mix (Agilent Technol-
ogies) with a probe and primer set to the B. hermsii flaB gene [35].
The number of spirochetes per ml of blood in the mice was
calculated from a standard curve of a 10-fold serial dilution of a
known number of spirochetes spiked into the SideStep Lysis and
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Stabilization buffer along with 5 ml of uninfected blood, diluted
1:10 in sterile distilled water, and 3 ml used as template.
Tick infections
Mice were inoculated by i.p. injection with 500 spirochetes of
the wild-type or Vmp+R strain, or 1.56108 spirochetes of the
Vmp2 strain and monitored daily for the first peak of infection by
collecting a thick drop of blood from the tail vein. Immediately
prior to tick feeding, two 5 ml drops of blood were taken from each
mouse and each placed in 95 ml Lysis and Stabilization Buffer
(Agilent Technologies) and frozen at –80uC for quantification of
spirochetemia levels by QPCR. Approximately 75 O. hermsi SIS
second-stage nymphs [35] were allowed to feed on each of the
three infected mice to acquire the wild-type, Vmp2 mutant, or
Vmp+R reconstituted strains. The Dvtp, vtp+R and wild-type
spirochetes were quantified in mice prior to tick-feeding by
examination of a dried blood smear stained with Giemsa and
spirochetes counted by bright-field microscopy. Ticks were fed on
mice that were anesthetized with pentobarbital (0.5 mg/10 g body
wt) (Abbott Laboratories, North Chicago, IL) via intraperitoneal
injection. The hair on the abdomen of the mouse was sheared with
electric clippers and ticks were placed on the abdomen and
allowed to feed to engorgement for 20 to 60 minutes. One or two
ticks from each group were squashed in PBS immediately after
feeding and examined by dark-field microscopy to confirm the
spirochete acquisition. Engorged ticks were maintained at 85%
relative humidity, 21uC and a natural photoperiod for subsequent
examination and transmission experiments.
Tick transmission experiments with the Dvtp mutant
The experimental infectious cycle with ticks and mice was
initiated by inoculating mice intraperitoneally with a culture
suspension of wild-type, Dvtp mutant or the vtp+R strain.
Uninfected second nymphs and adult O. hermsi ticks were allowed
to engorge on mice as described above. Ticks were dissected and
examined for their infection and spirochete phenotype (see below)
at selected time points from 7 to 448 days after feeding on infected
mice (Table 1). Other ticks in the same cohorts were allowed to
feed again on mice at selected times from 70 to 386 days after they
had acquired spirochetes to determine the infectiousness of the
three B. hermsii strains by tick bite (Table 3). Tick transmission
experiments were performed with 5 ticks applied to the belly of 10
mice, 12 ticks on 2 mice, and 20 ticks on 4 mice. After ticks fed, the
mice were examined daily for 10 days by microscopic examination
of blood collected from the tail vein. When mice became
spirochetemic, thin smears of blood were prepared on microscope
slides for subsequent analysis to determine the serotype of the
spirochetes. The 16 mice fed upon by infected ticks were kept for 3
to 4 months, at which time serum samples were collected for
serological tests for anti-B. hermsii antibodies determined by IFA
with fixed, whole cells of B. hermsii [83,84].
Indirect immunofluorescence antibody (IFA) assays
Double-labeled IFA assays were performed on thin blood
smears and tick tissues to detect spirochetes and determine if the
spirochetes were producing Vlp7 or Vtp. Drops of blood were
collected from the tip of the tail vein of the mice as described
above, thin smears were made on microscope slides, dried at RT,
fixed in 100% methanol for 20 min and stored at 4uC. The midgut
and salivary gland tissues from potentially infected ticks were
dissected at various times after their acquisition of spirochetes.
These tissues were dissected from single ticks partially immersed in
PBS, rinsed and prepared on individual slides as described [23],
fixed with 100% acetone and stored at 4uC until examined.
The blood and tick tissues were incubated with mouse
monoclonal anti-Vtp antibody H4825 [25] or mouse monoclonal
anti-Vlp7 antibody H9326 [82] undiluted for 30 min, washed in
PBS for 15 min, followed by a goat anti-mouse-FITC
(Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD)
diluted 1:100 for 30 min and washed again. The slides were then
incubated with a rabbit hyperimmune anti-B. hermsii serum 2779
(unpublished) at 1:50 for 30 min, washed for 15 min in PBS,
followed by goat anti-rabbit-RITC (Kirkegaard & Perry Labo-
ratories, Inc.) at 1::100 dilution. After a final wash and rinse with
water, the samples were mounted with glycerol and examined
with a Nikon Eclipse E800 epifluorescence microscope at 400X
with two filters specific for fluorescein and rhodamine.
Spirochetes were counted and scored as positive or negative
for Vtp or Vlp7.
Six ticks from each cohort infected with the wild-type, Vmp2
mutant, or Vmp+R strain were dissected at 98–105 days after the
ticks had fed and subsequently molted. For the Dvtp experiments, 5
ticks were examined at each sampling time-point for spirochetes
producing Vtp (Table 1), while just one tick per time-point was
examined for spirochetes producing Vlp7 (Table 2).
Supporting Information
Figure S1 Southern blot analysis of digested DNA of the
wild-type (WT) and two Vmp2 mutant clones. Two PsiI
restriction sites flank the flgBp-kan insertion and one MfeI site is
located just upstream of flgBp-kan (Fig 1). Both restriction digests
resulted in a fragment that was 216 bp larger in the Vmp2
mutants than in the wild-type (WT). Southern blots of genomic
DNA digested with PsiI or MfeI from the WT and two Vmp2
mutant clones were probed for vlp7 and the kanamycin-resistance
gene, kan. For each digest, the probe to vlp7 hybridized with two
bands in each strain: a common band corresponding to the silent
vlp7 cassette located on another linear plasmid [16] and a band
corresponding to the vlp7 at the expression site. A 0.2 kb shift in
the fragment size for both restriction digests between the wild-
type and the mutants indicates the mutation occurred at the
telomeric expression locus of lp28-1. The probe to kan hybridized
to the mutants on the same restriction fragment containing the
vlp7 at the expression site. If the mutation had occurred in a long
expression plasmid [7], then the shift in the MfeI-digested DNA
would have been larger than in the PsiI-digested DNA. The
predicted size of the MfeI fragment that the vlp7 and kan probes
would have hybridized to in the expression site of the mutants
would have been 4.2 kb (a 1.4 kb shift). Also, the vlp7 probe to
the silent cassette hybridized to the same size fragment in the
wild-type and mutant strains, demonstrating that the mutation
did not occur in the silent vlp7 cassette. Therefore, the mutation
and inactivation of the expression locus must have occurred near
the telomere of lp28-1. Molecular size standards in kilobase pairs
(kb) are on the left.
(TIF)
Figure S2 Southern blots of undigested genomic DNA of
the wild-type (WT), Vmp2 and Vmp+R strains. Undigested
genomic DNA of the three strains was resolved by reverse-pulse-
field gel electrophoresis and transferred to a nylon membrane.
Southern blots were probed for vlp7, vlp36 (to identify the lp28-1
plasmid), the kanamycin-resistance gene (kan), or the gentamicin-
resistance gene (aacC1). Agarose gel stained with Gel Red (A). The
probe for vlp7 hybridized to two plasmids in all strains, one
containing the silent vlp7 cassette and the other containing the vlp7
in the expression site on lp28-1 (B). The vlp36 probe hybridized to
the lp28-1 plasmid in all strains (C). The kan probe hybridized only
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to the Vmp2 mutant (D) and the aacC1 probe hybridized only to
the Vmp+R strain (E). Molecular size standards in kilobase pairs
(kb) are on the left with the Ladder Lambda DNA-MonoCut Mix
(New England Biolabs).
(TIF)
Figure S3 Plasmids used in the construction of the
Vmp2 mutant and Vmp+R reconstituted strains. Plasmid
pExpKO (A) was used in the transformation of wild-type B. hermsii
DAH 2E7 to construct the Vmp2 mutant by inactivating the vmp
expression site by homologous recombination. Plasmid pLp28-1G
(B) was used in the transformation of wild-type B. hermsii DAH 2E7
to construct the wild-type lp28-1 marked with the gentamicin-
resistance cassette.
(TIF)
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